SALT LAKE CITY - March 25, 2025 (NEWMEDIAWIRE) - Clene Inc. (NASDAQ: CLNN), along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)), today announced its participation in the Jones Las Vegas Technology and Innovation Conference, to be held April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada.
The Jones Conference is recognized for bringing together a select group of innovative companies and institutional investors for a two-day event. The event will be focused on one-on-one (1x1) meetings, fireside chats, panels, and networking. Organized by JonesTrading, with marketing support from B2i Digital, Inc., the event offers an opportunity for direct dialogue between senior company executives and investors seeking to engage with leadership teams.
“We look forward to participating in the Jones Conference, which provides an opportunity to share our progress and connect directly with investors in a setting that fosters productive conversations,” said Rob Etherington, CEO and President of Clene.
“JonesTrading is pleased to host a conference that brings together companies and investors for thoughtful and in-depth discussions,” said Alan Hill, CEO of JonesTrading. “We remain focused on creating a forum where public companies can communicate directly with the investment community.”
“As the Marketing Partner, B2i Digital is working to ensure that companies participating in the Jones Conference have a platform to reach investors who are actively seeking new ideas and opportunities,” said David Shapiro, CEO of B2i Digital, Inc. “We partner with the leading investor events in the US and are honored to be a part of this conference with its cutting-edge companies, serious investors and valued sponsors.”
The conference will feature keynote addresses from Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization, along with a Jones-hosted Golf Event and Cocktail Reception.
For more information about the Jones Las Vegas Technology and Innovation Conference, including a list of participating companies, visit their B2i Digital Featured Conference page.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc.), is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and unction via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
About JonesTrading
JonesTrading Institutional Services, LLC ("JonesTrading") is a leading full-service investment banking firm providing capital markets, M&A, and strategic advisory services to corporate clients. The firm is dedicated to building lasting partnerships by delivering innovative solutions, deep industry expertise, and tailored strategies that drive value and success. Founded in 1975, JonesTrading has established itself as the global leader in block trading and a premier liquidity provider to institutional investors. The firm's offerings also include derivatives trading, outsourced trading, electronic trading, prime services, private markets trading, and research/market intelligence. Member FINRA and SIPC.
For more information, please visit jonestrading.com.
JonesTrading Media Contact:
Megan Doyle
VP Corporate Access
325 Hudson Street
New York, NY 10013
https://www.jonestrading.com
800.377.7980
mdoyle@jonestrading.com
https://www.facebook.com/pages/JonesTrading-Institutional-Services-LLC/257514941601310
https://www.linkedin.com/company/jonestrading/
https://x.com/jonestrading
About B2i Digital, Inc.
B2i Digital, Inc. leverages the latest digital marketing technologies to tell a company's story to retail investors, institutional investors, and research analysts. B2i Digital creates robust profiles for companies and service providers on its platform, b2idigital.com, and launches targeted digital marketing campaigns to bring the most relevant audience to each company. The company was founded in 2021 by David Shapiro, previously the Chief Marketing Officer for Maxim Group LLC and its investor awareness platform, M-Vest.com.
B2i Digital Contact Information:
David Shapiro
Chief Executive Officer
B2i Digital, Inc.
https://b2idigital.com/
212.579.4844 Office
david@b2idigital.com
https://www.linkedin.com/in/davidshapironyc
https://www.linkedin.com/company/b2i-digital
https://x.com/b2idigital
https://www.facebook.com/b2idigital
https://www.instagram.com/b2i_digital
https://www.youtube.com/@b2idigital
https://stocktwits.com/B2iDigital
https://www.reddit.com/user/b2idigital/
https://www.pinterest.com/b2idigital/
https://www.tiktok.com/@b2idigital
https://www.threads.net/@b2i_digital
https://bsky.app/profile/b2idigital.bsky.social
View the original release on www.newmediawire.com
